Also, about 70% of breast cancer patients are hormone receptor positive.[1] Tamoxifen, a selective estrogen receptor modulator (SERM), is a well-known adjuvant endocrine treatment for estrogen receptor (ER)-positive breast cancer patients. The gene discussed is NR4A1; the disease is breast cancer.